Search results
Ionis to hold first quarter 2024 financial results webcast
WKBN 27 Youngstown· 3 days agoEastern Time to discuss its first quarter 2024 financial results. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has ...
How mRNA Is Rewriting the Rules of Cancer Treatment
SciTechDaily· 2 days agoMIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful...
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological...
Rome Sentinel· 4 days agoSkyhawk Therapeutics, Inc. (PRNewsfoto/Skyhawk Therapeutics)
Scientists discover potential biomarkers of environmental exposures in Parkinson's disease
Medical Xpress· 2 hours agoA team of Northwestern Medicine investigators has discovered novel DNA methylation patterns in the blood of patients with Parkinson's disease, according to findings published in Annals of Neurology ...
Roquefort Therapeutics readies to partner as after making significant pre-clinical headway
Proactive Investors· 9 hours agoRoquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said the significant preclinical progress has...
Arrowhead begins trial for kidney disease treatment By Investing.com
Investing.com· 2 days agoArrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR) has initiated a Phase 1/2a clinical trial of...
Avidity Biosciences director Levin sells $114,123 in company stock By Investing.com
Investing.com· 4 days agoA recent filing with the Securities and Exchange Commission has revealed that Arthur A. Levin, a...
What consumers should know about the milk testing positive for bird flu
NPR· 2 days agoSome genetic material may be left behind after the pasteurization process, such as DNA or RNA, the...
Leerink Partnrs Weighs in on Cartesian Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:RNAC)
ETF DAILY NEWS· 14 hours agoCartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for Cartesian Therapeutics in a report released on Tuesday ...
Equities Analysts Set Expectations for Sarepta Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:SRPT)
ETF DAILY NEWS· 12 hours agoSarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Equities research analysts at Zacks Research cut their FY2026 EPS estimates for Sarepta Therapeutics in a report released on Tuesday, ...